vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and BRC Group Holdings, Inc. (RILY). Click either name above to swap in a different company.
BRC Group Holdings, Inc. is the larger business by last-quarter revenue ($188.3M vs $183.1M, roughly 1.0× Amphastar Pharmaceuticals, Inc.). BRC Group Holdings, Inc. runs the higher net margin — 47.9% vs 13.3%, a 34.6% gap on every dollar of revenue. On growth, Amphastar Pharmaceuticals, Inc. posted the faster year-over-year revenue change (-1.8% vs -21.9%). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs -15.4%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
AMPH vs RILY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $188.3M |
| Net Profit | $24.4M | $90.3M |
| Gross Margin | 46.8% | 79.5% |
| Operating Margin | 19.4% | 32.3% |
| Net Margin | 13.3% | 47.9% |
| Revenue YoY | -1.8% | -21.9% |
| Net Profit YoY | -35.7% | 1710.8% |
| EPS (diluted) | $0.51 | $2.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $188.3M | ||
| Q3 25 | $191.8M | $215.3M | ||
| Q2 25 | $174.4M | $188.2M | ||
| Q1 25 | $170.5M | $197.2M | ||
| Q4 24 | $186.5M | $241.0M | ||
| Q3 24 | $191.2M | $225.5M | ||
| Q2 24 | $182.4M | $256.0M | ||
| Q1 24 | $171.8M | $263.4M |
| Q4 25 | $24.4M | $90.3M | ||
| Q3 25 | $17.4M | $91.1M | ||
| Q2 25 | $31.0M | $139.5M | ||
| Q1 25 | $25.3M | $-10.0M | ||
| Q4 24 | $38.0M | $-5.6M | ||
| Q3 24 | $40.4M | $-284.4M | ||
| Q2 24 | $37.9M | $-433.6M | ||
| Q1 24 | $43.2M | $-49.2M |
| Q4 25 | 46.8% | 79.5% | ||
| Q3 25 | 51.4% | 83.7% | ||
| Q2 25 | 49.6% | 81.3% | ||
| Q1 25 | 50.0% | 81.4% | ||
| Q4 24 | 46.5% | 79.8% | ||
| Q3 24 | 53.3% | 82.1% | ||
| Q2 24 | 52.2% | 84.5% | ||
| Q1 24 | 52.4% | 85.3% |
| Q4 25 | 19.4% | 32.3% | ||
| Q3 25 | 13.2% | 30.4% | ||
| Q2 25 | 24.2% | 5.7% | ||
| Q1 25 | 21.9% | -31.2% | ||
| Q4 24 | 24.2% | -69.2% | ||
| Q3 24 | 29.8% | -36.4% | ||
| Q2 24 | 30.3% | -90.8% | ||
| Q1 24 | 27.9% | -6.1% |
| Q4 25 | 13.3% | 47.9% | ||
| Q3 25 | 9.0% | 42.3% | ||
| Q2 25 | 17.8% | 74.1% | ||
| Q1 25 | 14.8% | -5.1% | ||
| Q4 24 | 20.4% | -2.3% | ||
| Q3 24 | 21.1% | -126.1% | ||
| Q2 24 | 20.8% | -169.4% | ||
| Q1 24 | 25.1% | -18.7% |
| Q4 25 | $0.51 | $2.78 | ||
| Q3 25 | $0.37 | $2.91 | ||
| Q2 25 | $0.64 | $4.50 | ||
| Q1 25 | $0.51 | $-0.39 | ||
| Q4 24 | $0.74 | $-0.01 | ||
| Q3 24 | $0.78 | $-9.39 | ||
| Q2 24 | $0.73 | $-14.35 | ||
| Q1 24 | $0.81 | $-1.71 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $226.6M |
| Total DebtLower is stronger | $608.7M | $1.4B |
| Stockholders' EquityBook value | $788.8M | $-171.5M |
| Total Assets | $1.6B | $1.7B |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $226.6M | ||
| Q3 25 | $276.2M | $184.2M | ||
| Q2 25 | $231.8M | $267.4M | ||
| Q1 25 | $236.9M | $138.3M | ||
| Q4 24 | $221.6M | $146.9M | ||
| Q3 24 | $250.5M | $159.2M | ||
| Q2 24 | $217.8M | $236.9M | ||
| Q1 24 | $289.6M | $190.7M |
| Q4 25 | $608.7M | $1.4B | ||
| Q3 25 | $608.6M | $1.3B | ||
| Q2 25 | $607.7M | $1.3B | ||
| Q1 25 | $603.9M | $1.4B | ||
| Q4 24 | $601.6M | $1.5B | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $-171.5M | ||
| Q3 25 | $776.7M | $-260.5M | ||
| Q2 25 | $757.5M | $-351.7M | ||
| Q1 25 | $751.3M | $-496.8M | ||
| Q4 24 | $732.3M | $-488.2M | ||
| Q3 24 | $727.7M | $-497.6M | ||
| Q2 24 | $713.3M | $-218.3M | ||
| Q1 24 | $672.4M | $228.4M |
| Q4 25 | $1.6B | $1.7B | ||
| Q3 25 | $1.7B | $1.7B | ||
| Q2 25 | $1.6B | $1.5B | ||
| Q1 25 | $1.6B | $1.5B | ||
| Q4 24 | $1.6B | $1.8B | ||
| Q3 24 | $1.5B | $2.2B | ||
| Q2 24 | $1.5B | $3.2B | ||
| Q1 24 | $1.6B | $5.0B |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $26.2M |
| Free Cash FlowOCF − Capex | $24.6M | — |
| FCF MarginFCF / Revenue | 13.4% | — |
| Capex IntensityCapex / Revenue | 4.5% | — |
| Cash ConversionOCF / Net Profit | 1.35× | 0.29× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $26.2M | ||
| Q3 25 | $52.6M | $-60.6M | ||
| Q2 25 | $35.6M | $-25.6M | ||
| Q1 25 | $35.1M | $184.0K | ||
| Q4 24 | $29.0M | $-2.7M | ||
| Q3 24 | $60.0M | $19.5M | ||
| Q2 24 | $69.1M | $111.5M | ||
| Q1 24 | $55.3M | $135.4M |
| Q4 25 | $24.6M | — | ||
| Q3 25 | $47.2M | — | ||
| Q2 25 | $25.0M | — | ||
| Q1 25 | $24.4M | — | ||
| Q4 24 | $16.6M | — | ||
| Q3 24 | $46.2M | — | ||
| Q2 24 | $63.1M | — | ||
| Q1 24 | $46.5M | — |
| Q4 25 | 13.4% | — | ||
| Q3 25 | 24.6% | — | ||
| Q2 25 | 14.3% | — | ||
| Q1 25 | 14.3% | — | ||
| Q4 24 | 8.9% | — | ||
| Q3 24 | 24.1% | — | ||
| Q2 24 | 34.6% | — | ||
| Q1 24 | 27.1% | — |
| Q4 25 | 4.5% | — | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 6.1% | — | ||
| Q1 25 | 6.3% | — | ||
| Q4 24 | 6.7% | — | ||
| Q3 24 | 7.2% | — | ||
| Q2 24 | 3.3% | — | ||
| Q1 24 | 5.1% | — |
| Q4 25 | 1.35× | 0.29× | ||
| Q3 25 | 3.03× | -0.66× | ||
| Q2 25 | 1.15× | -0.18× | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
